C4 Therapeutics Advances Cemsidomide Through Phase 2 Development as Potential Best-in-Class Multiple Myeloma Treatment
核心洞察
C4 Therapeutics plans to initiate the Phase 2 MOMENTUM trial of cemsidomide in Q1 2026, targeting fourth-line or later relapsed/refractory multiple myeloma (搜索) patients with a recommended dose of 100 µg.
Phase 1 data demonstrated compelling anti-myeloma activity with 53% overall response rate at the 100 µg dose level in heavily pretreated patients, supporting cemsidomide's potential best-in-class profile.
The company has developed a regulatory pathway for two potential accelerated approvals and plans to submit a new drug application by year-end 2028.
C4 Therapeutics has outlined an ambitious clinical development strategy for cemsidomide, its investigational IKZF1 (搜索)/3 degrader, positioning the drug as a potential foundational therapy for multiple myeloma (搜索) patients across multiple lines of treatment. The company announced plans to initiate two pivotal trials in 2026 while expanding its discovery pipeline into neurological diseases.
Phase 2 MOMENTUM Trial Set for Q1 2026 Launch
The Phase 2 MOMENTUM trial will evaluate cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma (搜索) who have received at least three prior anti-myeloma regimens. The study will enroll approximately 100 patients and use 100 µg as the recommended Phase 2 dose, selected after discussions with the FDA.
"We begin 2026 with compelling opportunities ahead, anchored by cemsidomide's path to become a foundational medicine for multiple myeloma (搜索) by reaching patients across multiple lines of therapy," said Andrew Hirsch, president and chief executive officer of C4 Therapeutics.
The trial's primary endpoint is overall response rate per International Myeloma Working Group response criteria, as assessed by an independent review committee. Enrolled patients must have previously received an IKZF1 (搜索)/3 degrader, a proteasome inhibitor, an anti-CD38 antibody, and a T-cell engager or CAR-T therapy.
Promising Phase 1 Results Drive Development Strategy
C4 Therapeutics completed enrollment in its Phase 1 trial of cemsidomide and dexamethasone, presenting data that demonstrated the two highest dose levels achieved significant clinical activity. The 75 µg dose achieved a 40% overall response rate, while the 100 µg dose reached a 53% overall response rate in heavily pretreated patients.
These results reinforce cemsidomide's potential best-in-class profile among IKZF1 (搜索)/3 degraders, a class of drugs that serve as established backbone therapies across lines of multiple myeloma (搜索) treatment. The Phase 1 data showed cemsidomide's differentiated safety and tolerability profile alongside potentially class-leading anti-myeloma activity.
Dual Regulatory Pathway for Accelerated Approvals
The company has developed a regulatory path incorporating FDA feedback that positions cemsidomide to potentially receive two distinct accelerated approvals. The first would target fourth line or later treatment with cemsidomide and dexamethasone, while the second would address second line or later treatment combining cemsidomide with a BCMA (搜索) BiTE therapy.
C4 Therapeutics plans to present initial overall response rate data for the MOMENTUM trial in the second half of 2027, followed by efficacy and safety data in mid-2028. The company aims to submit a new drug application for potential accelerated approval in fourth line or later treatment by year-end 2028.
Combination Strategy with Bispecific Antibodies
In Q2 2026, C4 Therapeutics will initiate a Phase 1b trial evaluating cemsidomide in combination with elranatamab, an FDA-approved B-cell maturation antigen CD3 targeted bispecific antibody. The study will evaluate different cemsidomide dose levels beginning with 75 µg in patients who have received one to four prior lines of therapy.
The company plans to present Phase 1b data from all cohorts evaluating this combination in mid-2027, with the goal of initiating a Phase 3 trial evaluating cemsidomide in combination with a BCMA (搜索) BiTE by early 2028.
Expanded Discovery Pipeline Targets Neurological Diseases
Beyond multiple myeloma (搜索), C4 Therapeutics has implemented a new discovery strategy focused on developing degrader medicines for five novel targets that modulate three clinically validated pathways for inflammation, neuro-inflammation and neuro-degenerative diseases. This strategy leverages the company's expertise in developing highly catalytic orally bioavailable degraders that penetrate the blood-brain barrier.
The company has extended its capabilities to identify molecular glue degraders using DNA-encoded library technology and aims to deliver up to three investigational new drug applications by year-end 2028.
Multiple Myeloma Treatment Landscape
Multiple myeloma (搜索) is a rare blood cancer affecting plasma cells, with approximately 36,000 people diagnosed annually in the United States. Despite treatment advances, the disease remains incurable, creating significant unmet medical need for more effective therapies.
Cemsidomide is an investigational, orally bioavailable molecular glue degrader of IKZF1 (搜索)/3 transcription factors that drive multiple myeloma (搜索). The drug is designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, potentially overcoming drug resistance and improving patient outcomes.
Financial Position Supports Development Timeline
C4 Therapeutics has secured cash runway through the end of 2028, providing funding through key value inflection points including the completion of pivotal trials and potential regulatory submissions. The company also maintains discovery collaborations with Merck KGaA, Roche, and Biogen, with plans to deliver at least one development candidate to a collaboration partner by year-end 2026.